Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Optimizing PTCy Dose and Timing
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
- Status
- UNKNOWN
- Phase
- PHASE2
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Status
- RECRUITING
- Phase
- PHASE2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
- Status
- COMPLETED
- Phase
- PHASE3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Status
- RECRUITING
- Phase
- PHASE3
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE3
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Status
- COMPLETED
- Phase
- PHASE2
Split-Dose R-CHOP for Older Adults With DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Breast Cancer Treatment Based on Organ-like Culture
- Status
- UNKNOWN
- Phase
- N/A
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
- Status
- COMPLETED
- Phase
- PHASE1